Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.55 |
| ▸ | PGR | P06401 | 10/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.49 |
| ▸ | SHBG | P04278 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24476246 | 0.91 | AR (0.54) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL24476335 | 0.88 | AR (0.56) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL24476299 | 0.85 | CYP3A4 (0.68) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL9340441 | 0.84 | AR (0.59) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL24476334 | 0.84 | AR (0.59) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL2835215 | 0.82 | PGR (0.72) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL6245967 | 0.82 | PGR (0.72) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL6873042 | 0.82 | PGR (0.72) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL23805202 | 0.82 | PGR (0.72) | ARPGRNR3C2CYP3A4ABCB11 | |
| SCHEMBL24476199 | 0.82 | AR (0.63) | ARPGRNR3C2CYP3A4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169672-A1 | COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169672-A1 | COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER | KLK3, AR, ACP3 | AR 2/4885PGR 777/4885NR3C2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.